Clinical Trial

A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of AK138D1 as monotherapy or in combination with ivonescimab in patients with advanced non-small cell lung cancer. Participants will receive study treatment with AK138D1 alone or in combination with ivonescimab, undergo safety assessments and tumor evaluations, and be followed for treatment tolerability, antitumor activity, and clinical outcomes.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-30
Trial Details
NCT Number NCT07623356
Lead Sponsor Akeso
Conditions Non-Small Cell Lung Cancer
Enrollment 265 participants
Start Date 2026-07-07
Primary Completion 2028-06-18 (estimated)
Study Completion 2030-07-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-29